Mecasermin rinfabate is a Recombinant Protein owned by Insmed, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.

Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor and and human insulin-like growth factor-binding protein-3 (rhIGFBP-3)0. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.

The revenue for Mecasermin rinfabate is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mecasermin rinfabate NPV Report.

Mecasermin rinfabate is originated and owned by Insmed. Takeda Pharmaceutical is the other company associated in development or marketing of Mecasermin rinfabate.

Mecasermin rinfabate Overview

Mecasermin rinfabate (Iplex) is a recombinant human biologic protein complex of insulin-like growth factor-1 (IGF-1). It is formulated as injectable solution for subcutaneous route of administration. It is indicated in the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD).

Mecasermin rinfabate (Iplex) is under development for treatment of chronic respiratory morbidity (CRM) including bronchopulmonary dysplasia (BPD), retinopathy of prematurity and severe intraventricular hemorrhage. It was also under development for the treatment of burns, myotonic dystrophy, Rabson–Mendenhall syndrome, Leprechaunism, laron syndrome, type A and type B extreme insulin resistance syndrome.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Mecasermin rinfabate

Report Segments
  • Innovator (NME)
Drug Name
  • Mecasermin rinfabate
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Genetic Disorders
  • Hormonal Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.